Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2017 Dec 20;6(2):258-261.
doi: 10.1002/ccr3.1288. eCollection 2018 Feb.

Stevens-Johnson syndrome/toxic epidermal necrolysis associated with zonisamide

Karina L Vivar  1 , Kimberly Mancl  1 , Lucia Seminario-Vidal  1
Affiliations
Case Reports

Stevens-Johnson syndrome/toxic epidermal necrolysis associated with zonisamide

Karina L Vivar et al. Clin Case Rep. .

Abstract

This report highlights zonisamide as a potential cause of serious cutaneous reactions as well as its cross-reactivity with other sulfonamides. Here, we present a case of SJS-TEN due to zonisamide, which was effectively treated with IVIg. Subsequently, the patient was transitioned to levetiracetam for seizure control.

Keywords: Drug rash; Stevens–Johnson syndrome; pediatric; toxic epidermal necrolysis; zonisamide.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Clinical photograph of patient demonstrating dusky, erythematous macules, and papules as well as crusting and erosions of the lips.
Figure 2
Figure 2
Clinical photograph of patient's bullae and full‐thickness epidermal desquamation.
Figure 3
Figure 3
Biopsy specimen demonstrating full‐thickness epidermal necrosis, 100X.
See this image and copyright information in PMC

References

    1. U.S. Food and Drug Administration, Center for Drug Evaluation and Research . Zonegran NDA 20‐789 approval letter, March 27, 2000. Available at https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020789_Zonegran_... (accessed 9 May 2017).
    1. Biton, V. 2007. Clinical pharmacology and mechanism of action of zonisamide. Clin. Neuropharmacol. 30:230–240. - PubMed
    1. Baulac, M. , Brodie M. J., Patten A., Segieth J., and Giorgi L.. 2012. Efficacy and tolerability of zonisamide versus controlled‐release carbamazepine for newly diagnosed partial epilepsy: a phase 3, randomized, double‐blind, non‐inferiority trial. Lancet Neurol. 11:579–588. - PubMed
    1. Buoli, M. , Grassi S., Ciappolino V., Serati M., and Altamura A. C.. 2017. The use of zonisamide for the treatment of psychiatric disorders: a systematic review. Clin. Neuropharmacol. 40:85–92. - PubMed
    1. Baulac, M. , Patten A., and Giorgi L.. 2014. Long‐term safety and efficacy of zonisamide versus carbamazepine monotherapy for treatment of partial seizures in adults with newly diagnosed epilepsy: results of a phase III, randomized, double‐blind study. Epilepsia 55:1534–1543. - PubMed

Publication types

LinkOut - more resources